I don't think there was ever a chance that ALNY would develop PCS further without partnering. The key question on that CC was whether they needed to run more studies before partnering, and they clearly answered no. So I don't think "shelving" is the right term. I don't read much into the delivery agreement, except being confused (along with Dirk) as to why they didn't have rights to that platform already.
Any comments here may have previously been disseminated on Twitter @BioDueDiligence or at www.biotechduediligence.com